Lannett Company Inc. (NYSE: LCI), a company that develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications, announced on Tuesday that it has started marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug, Aggrenox Capsules, 25 mg/200 mg, from Boehringer Ingelheim Pharmaceuticals Inc.
According to contract research organisation, IQVIA, total US sales of Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, amounted to around USD158m for the 12 months ended April 2019, although actual generic market values are likely to be lower.
Tim Crew, chief executive officer of Lannett, stated: "The launch of Aspirin and Extended-Release Dipyridamole Capsules, an internally developed product, represents a meaningful opportunity. We continue to make progress on a number of operational fronts. Since January of this year, we have improved our capital structure with open market purchases of approximately USD62 million of our Term loans, which is in addition to the approximately USD67 million of required annual loan amortisation, added drug development expertise to our board of directors and, including Aspirin and Extended-Release Dipyridamole, launched seven new products."
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling